KLRK1 and autoimmune disease: Given that the expression of NKG2D and NKG2D-L is regulated by a variety of factors, a number of targeted antibodies can be formulated to block the expression of NKG2D or NKG2D-L, thereby inhibiting the interaction; this may have important implications for the treatment of autoimmune diseases.